PriceTargets.com logo

Allogene Therapeutics - ALLO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.73
  • Forecasted Upside: 374.80%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$2.05 As of 11/20/2024 01:00 AM ET
▼ -0.07 (-3.30%)

This chart shows the closing price for ALLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allogene Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLO

Analyst Price Target is $9.73
▲ +374.80% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $9.73, with a high forecast of $14.00 and a low forecast of $4.60. The average price target represents a 374.80% upside from the last price of $2.05.

This chart shows the closing price for ALLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Allogene Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024William BlairReiterated RatingOutperform
11/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $9.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
10/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/9/2024CitigroupBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
8/9/2024Truist FinancialReiterated RatingBuy ➝ Buy$17.00 ➝ $14.00
8/8/2024OppenheimerInitiated CoverageOutperform$13.00 ➝ $11.00
8/8/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$35.00 ➝ $14.00
5/31/2024Piper SandlerInitiated CoverageOverweight$11.00
5/21/2024OppenheimerLower TargetOutperform ➝ Outperform$14.00 ➝ $13.00
5/16/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.00
5/15/2024Truist FinancialReiterated RatingBuy ➝ Buy$17.00
5/14/2024Stifel NicolausBoost TargetHold ➝ Hold$4.40 ➝ $4.60
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$10.00
2/27/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$9.00 ➝ $8.00
1/19/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $10.00
1/5/2024GuggenheimDowngradeBuy ➝ Neutral
1/5/2024JMP SecuritiesReiterated RatingOutperform ➝ Market Perform
12/8/2023CitigroupInitiated CoverageBuy$7.00
11/15/2023HC WainwrightLower TargetBuy ➝ Buy$23.00 ➝ $12.00
9/25/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$11.00 ➝ $9.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$23.00
8/3/2023OppenheimerReiterated RatingOutperform ➝ Outperform$28.00
7/12/2023Truist FinancialLower Target$20.00 ➝ $18.00
5/5/2023JMP SecuritiesLower Target$19.00 ➝ $15.00
5/4/2023Stifel NicolausLower Target$8.00 ➝ $7.50
4/20/2023HC WainwrightReiterated RatingBuy$23.00
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00
4/4/2023HC WainwrightLower TargetBuy$29.00 ➝ $23.00
3/22/2023William BlairReiterated RatingOutperform
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$6.00
3/2/2023JMP SecuritiesLower TargetMarket Perform$23.00 ➝ $19.00
3/1/2023Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $22.00
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00
3/1/2023The Goldman Sachs GroupLower TargetBuy$35.00 ➝ $31.00
3/1/2023OppenheimerLower TargetOutperform$32.00 ➝ $28.00
3/1/2023Truist FinancialLower Target$29.00 ➝ $20.00
3/1/2023B. RileyLower Target$18.00 ➝ $15.00
1/24/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$20.00 ➝ $11.00
1/6/2023Robert W. BairdUpgradeNeutral ➝ Outperform$12.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$15.00
12/12/2022Bank of AmericaDowngradeBuy ➝ Underperform$24.00 ➝ $9.00
12/1/2022OppenheimerReiterated RatingOutperform ➝ Outperform$32.00
11/21/2022HC WainwrightLower TargetBuy$43.00 ➝ $29.00
10/13/2022OppenheimerLower Target$32.00
9/27/2022JMP SecuritiesReiterated RatingBuy$23.00
9/22/2022B. RileyLower TargetBuy$21.00 ➝ $18.00
8/23/2022Truist FinancialLower Target$29.00
8/10/2022OppenheimerLower TargetOutperform$40.00 ➝ $35.00
8/10/2022Raymond JamesDowngradeOutperform ➝ Market Perform
7/15/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$9.00 ➝ $32.00
6/2/2022Robert W. BairdInitiated CoverageNeutral$11.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$12.00 ➝ $9.00
5/5/2022Raymond JamesLower Target$36.00 ➝ $13.00
4/11/2022JMP SecuritiesReiterated RatingBuy$23.00
3/29/2022William BlairReiterated RatingOutperform
3/7/2022The Goldman Sachs GroupLower TargetNeutral$20.00 ➝ $12.00
3/4/2022HC WainwrightReiterated RatingBuy$43.00
2/28/2022B. RileyLower TargetBuy$30.00 ➝ $21.00
1/11/2022HC WainwrightReiterated RatingBuy$43.00
1/4/2022GuggenheimLower Target$40.00 ➝ $35.00
12/17/2021JMP SecuritiesReiterated RatingBuy$27.00
12/14/2021Royal Bank of CanadaLower TargetOutperform ➝ Outperform$45.00 ➝ $35.00
10/20/2021CowenInitiated CoverageOutperform
10/12/2021JMP SecuritiesLower TargetHold ➝ Outperform$53.00 ➝ $27.00
10/8/2021HC WainwrightReiterated RatingBuy$43.00
10/8/2021Bank of AmericaLower TargetBuy$41.00 ➝ $32.00
10/8/2021Jefferies Financial GroupReiterated RatingBuy
10/8/2021Roth CapitalLower TargetHold ➝ Buy$60.00 ➝ $35.00
10/8/2021Stifel NicolausDowngradeBuy ➝ Hold$44.00 ➝ $18.00
10/8/2021William BlairReiterated RatingBuy
10/8/2021OppenheimerLower TargetOutperform$44.00 ➝ $40.00
10/8/2021Royal Bank of CanadaLower TargetHold ➝ Outperform$55.00 ➝ $45.00
10/8/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$71.00 ➝ $20.00
9/23/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$36.00
8/6/2021B. RileyLower TargetBuy$52.00 ➝ $40.00
8/5/2021OppenheimerLower TargetOutperform$52.00 ➝ $44.00
7/1/2021Jefferies Financial GroupReiterated RatingBuy$53.00
6/22/2021Jefferies Financial GroupInitiated CoverageBuy$53.00
5/20/2021Truist FinancialUpgradeHold ➝ Buy$34.00 ➝ $41.00
5/14/2021B. RileyInitiated CoverageBuy$52.00
4/22/2021HC WainwrightReiterated RatingBuy
4/12/2021OppenheimerReiterated RatingBuy
3/1/2021HC WainwrightBoost TargetBuy$40.00 ➝ $43.00
1/26/2021Stifel NicolausUpgradeHold ➝ Buy$33.00 ➝ $43.00
12/14/2020JPMorgan Chase & Co.Reiterated RatingHold
12/10/2020HC WainwrightReiterated RatingBuy$40.00
11/24/2020Bank of AmericaInitiated CoverageBuy$41.00
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$55.00
8/9/2020Jefferies Financial GroupReiterated RatingBuy
8/9/2020CowenReiterated RatingBuy
8/6/2020HC WainwrightReiterated RatingBuy$49.00
6/12/2020HC WainwrightLower TargetBuy$55.00 ➝ $49.00
6/8/2020SunTrust BanksBoost TargetHold$32.00 ➝ $50.00
6/1/2020JMP SecuritiesBoost Target$37.00 ➝ $53.00
6/1/2020The Goldman Sachs GroupBoost TargetBuy$45.00 ➝ $66.00
6/1/2020Raymond JamesDowngradeOutperform ➝ Market Perform
5/31/2020OppenheimerBoost TargetOutperform$50.00 ➝ $55.00
5/29/2020William BlairReiterated RatingBuy
5/29/2020HC WainwrightBoost TargetBuy$42.00 ➝ $55.00
5/29/2020Piper SandlerBoost TargetOverweight$50.00 ➝ $70.00
5/19/2020Roth CapitalUpgradeNeutral ➝ Buy$26.00 ➝ $60.00
5/15/2020GuggenheimUpgradeNeutral ➝ Buy
5/14/2020Jefferies Financial GroupBoost TargetBuy$37.00 ➝ $45.00
5/14/2020SunTrust BanksDowngradeBuy ➝ Hold$29.00 ➝ $32.00
5/13/2020HC WainwrightReiterated RatingBuy$35.00 ➝ $42.00
5/13/2020OppenheimerBoost TargetOutperform$44.00 ➝ $50.00
5/6/2020OppenheimerInitiated CoverageBuy$44.00
4/13/2020SunTrust BanksInitiated CoverageBuy$29.00 ➝ $29.00
3/24/2020OppenheimerReiterated RatingBuy$44.00
3/13/2020HC WainwrightInitiated CoverageBuy$35.00
3/4/2020Stifel NicolausInitiated CoverageHold$27.00
2/24/2020Berenberg BankInitiated CoverageHold$27.00
12/18/2019JMP SecuritiesInitiated CoverageOutperform$37.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 6 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 9 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 4 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 4 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Allogene Therapeutics logo
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.05
Low: $1.99
High: $2.14

50 Day Range

MA: $2.71
Low: $2.05
High: $3.22

52 Week Range

Now: $2.05
Low: $1.99
High: $5.78

Volume

2,443,430 shs

Average Volume

2,470,438 shs

Market Capitalization

$429.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Allogene Therapeutics?

The following Wall Street analysts have issued research reports on Allogene Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, Truist Financial Co., and William Blair.
View the latest analyst ratings for ALLO.

What is the current price target for Allogene Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Allogene Therapeutics in the last year. Their average twelve-month price target is $9.73, suggesting a possible upside of 374.8%. Truist Financial Co. has the highest price target set, predicting ALLO will reach $14.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.60 for Allogene Therapeutics in the next year.
View the latest price targets for ALLO.

What is the current consensus analyst rating for Allogene Therapeutics?

Allogene Therapeutics currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALLO.

What other companies compete with Allogene Therapeutics?

Other companies that are similar to Allogene Therapeutics include Fate Therapeutics, bluebird bio, Immunocore, Neumora Therapeutics and BioCryst Pharmaceuticals. Learn More about companies similar to Allogene Therapeutics.

How do I contact Allogene Therapeutics' investor relations team?

Allogene Therapeutics' physical mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 457-2700 and its investor relations email address is [email protected]. The official website for Allogene Therapeutics is www.allogene.com. Learn More about contacing Allogene Therapeutics investor relations.